Logo image of PHAT

PHATHOM PHARMACEUTICALS INC (PHAT) Stock Fundamental Analysis

NASDAQ:PHAT - US71722W1071 - Common Stock

11.91 USD
+0.96 (+8.77%)
Last: 8/22/2025, 8:00:00 PM
11.91 USD
0 (0%)
After Hours: 8/22/2025, 8:00:00 PM
Fundamental Rating

2

Overall PHAT gets a fundamental rating of 2 out of 10. We evaluated PHAT against 193 industry peers in the Pharmaceuticals industry. PHAT may be in some trouble as it scores bad on both profitability and health. PHAT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PHAT had negative earnings in the past year.
PHAT had a negative operating cash flow in the past year.
PHAT had negative earnings in each of the past 5 years.
In the past 5 years PHAT always reported negative operating cash flow.
PHAT Yearly Net Income VS EBIT VS OCF VS FCFPHAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

PHAT has a Return On Assets of -117.53%. This is in the lower half of the industry: PHAT underperforms 78.76% of its industry peers.
Industry RankSector Rank
ROA -117.53%
ROE N/A
ROIC N/A
ROA(3y)-85.69%
ROA(5y)-75.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PHAT Yearly ROA, ROE, ROICPHAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

PHAT has a better Gross Margin (86.23%) than 91.71% of its industry peers.
PHAT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHAT Yearly Profit, Operating, Gross MarginsPHAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

More info and screens

3

2. Health

2.1 Basic Checks

PHAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PHAT has been increased compared to 1 year ago.
The number of shares outstanding for PHAT has been increased compared to 5 years ago.
Compared to 1 year ago, PHAT has a worse debt to assets ratio.
PHAT Yearly Shares OutstandingPHAT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PHAT Yearly Total Debt VS Total AssetsPHAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -7.89, we must say that PHAT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.89, PHAT is doing worse than 64.25% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.89
ROIC/WACCN/A
WACC8.98%
PHAT Yearly LT Debt VS Equity VS FCFPHAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 3.58 indicates that PHAT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.58, PHAT is in the better half of the industry, outperforming 61.66% of the companies in the same industry.
A Quick Ratio of 3.54 indicates that PHAT has no problem at all paying its short term obligations.
PHAT's Quick ratio of 3.54 is fine compared to the rest of the industry. PHAT outperforms 63.21% of its industry peers.
Industry RankSector Rank
Current Ratio 3.58
Quick Ratio 3.54
PHAT Yearly Current Assets VS Current LiabilitesPHAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

PHAT shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.80%.
The Revenue has grown by 8001.47% in the past year. This is a very strong growth!
EPS 1Y (TTM)7.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.69%
Revenue 1Y (TTM)8001.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%439.36%

3.2 Future

PHAT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.45% yearly.
PHAT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 76.83% yearly.
EPS Next Y34.06%
EPS Next 2Y35.44%
EPS Next 3Y30.47%
EPS Next 5Y25.46%
Revenue Next Year215.77%
Revenue Next 2Y153.32%
Revenue Next 3Y119.98%
Revenue Next 5Y76.83%

3.3 Evolution

PHAT Yearly Revenue VS EstimatesPHAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
PHAT Yearly EPS VS EstimatesPHAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PHAT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PHAT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHAT Price Earnings VS Forward Price EarningsPHAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHAT Per share dataPHAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as PHAT's earnings are expected to grow with 30.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.44%
EPS Next 3Y30.47%

More info and screens

0

5. Dividend

5.1 Amount

PHAT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHATHOM PHARMACEUTICALS INC

NASDAQ:PHAT (8/22/2025, 8:00:00 PM)

After market: 11.91 0 (0%)

11.91

+0.96 (+8.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners67.01%
Inst Owner Change-10.27%
Ins Owners2.04%
Ins Owner Change1.88%
Market Cap844.90M
Analysts84
Price Target21.8 (83.04%)
Short Float %18.55%
Short Ratio3.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.52%
Min EPS beat(2)-12%
Max EPS beat(2)19.05%
EPS beat(4)2
Avg EPS beat(4)2.41%
Min EPS beat(4)-12%
Max EPS beat(4)19.05%
EPS beat(8)4
Avg EPS beat(8)1.13%
EPS beat(12)7
Avg EPS beat(12)1.55%
EPS beat(16)10
Avg EPS beat(16)1.86%
Revenue beat(2)1
Avg Revenue beat(2)6.56%
Min Revenue beat(2)-3.64%
Max Revenue beat(2)16.75%
Revenue beat(4)3
Avg Revenue beat(4)15.97%
Min Revenue beat(4)-3.64%
Max Revenue beat(4)27.14%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.92%
PT rev (3m)8.9%
EPS NQ rev (1m)-6.12%
EPS NQ rev (3m)-5.76%
EPS NY rev (1m)0%
EPS NY rev (3m)6.53%
Revenue NQ rev (1m)-0.84%
Revenue NQ rev (3m)-0.84%
Revenue NY rev (1m)-0.21%
Revenue NY rev (3m)-0.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.16
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.73
EYN/A
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-4.05
FCFYN/A
OCF(TTM)-4.05
OCFYN/A
SpS1.17
BVpS-4.85
TBVpS-4.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -117.53%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.23%
FCFM N/A
ROA(3y)-85.69%
ROA(5y)-75.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.91%
Cap/Sales 0.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.58
Quick Ratio 3.54
Altman-Z -7.89
F-Score3
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)156.3%
Cap/Depr(5y)171.47%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.69%
EPS Next Y34.06%
EPS Next 2Y35.44%
EPS Next 3Y30.47%
EPS Next 5Y25.46%
Revenue 1Y (TTM)8001.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%439.36%
Revenue Next Year215.77%
Revenue Next 2Y153.32%
Revenue Next 3Y119.98%
Revenue Next 5Y76.83%
EBIT growth 1Y-38.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.45%
EBIT Next 3Y40.64%
EBIT Next 5Y31.42%
FCF growth 1Y-98.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-99.86%
OCF growth 3YN/A
OCF growth 5YN/A